TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
about
Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitisReview article: dose optimisation of infliximab for acute severe ulcerative colitis.Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis.C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up studyReview article: the practical management of acute severe ulcerative colitis.Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease.Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors?Results of the 2nd part Scientific Workshop of the ECCO. II: Measures and markers of prediction to achieve, detect, and monitor intestinal healing in inflammatory bowel disease.Candidate mucosal and surrogate biomarkers of inflammatory bowel disease in the era of new technology.Tailoring anti-TNF therapy in IBD: drug levels and disease activity.Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.Global mucosal and serum cytokine profile in patients with ulcerative colitis undergoing anti-TNF therapy.The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study.Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.Can We Predict the Efficacy of Anti-TNF-α Agents?Role of miR-19a targeting TNF-α in mediating ulcerative colitis.Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.Endoscopic finding of spontaneous hemorrhage correlates with tumor necrosis factor alpha expression in colonic mucosa of patients with ulcerative colitis.Elevation of PRKCDBP, a novel transcriptional target of TNF-α, and its downregulation by infliximab in patients with ulcerative colitis.Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis
P2860
Q26823221-530697A3-785C-460B-8C6B-E605BE89B466Q30239077-65F657B0-0FBA-47FB-875A-D9E61BE9896BQ34084800-1FBEC898-1D94-44B3-A870-4182AE41E572Q35745374-0650E68F-8A9E-4760-9D8E-6345D8B58EF1Q35883580-0A74E750-EDDF-4707-8CAB-FE34E8328C2AQ36838066-A15ACD52-77EC-4228-AAA3-0BB4AAA81DE7Q37762230-080624F2-B2CE-4EC3-874C-15E2F6FB1803Q37937183-0D7212B1-4104-4F11-A817-B9DC68572E68Q37951110-6C7DE6D9-3155-4EF3-898F-2E7BB6B35573Q38176154-0A0D92D7-855A-41A9-91E0-3CA2B735CE6DQ38240881-134F44FD-46C2-457E-A3F6-3885F7A92763Q38501680-281619E7-B83E-40A4-B41D-7BD0330918B3Q38822920-5805B502-6D22-404E-B123-EF9129650ED9Q40056338-EA1DEBA4-B359-4197-B52B-9BDAF6406FF4Q41067868-A7AF3AE8-3367-454F-ACE0-320ED19121A0Q41451555-EEA08B9C-61A9-439F-8C96-09393838591BQ41482221-97C2AB0F-6C5A-4B94-81A1-46F483859401Q41660559-3CB30E6B-CC82-4560-9FB6-7BEE45DE7005Q43803974-C021983E-C28E-404E-A19D-F5572A265552Q43988900-E90446E8-CDDC-4262-ADC0-94439E460F37Q48250204-36D0F1E6-B66E-42D4-817C-21C903A748E6Q53723979-D8F32683-7265-4440-A2BE-4730F4A7962BQ54273411-3FBDB737-9917-48D6-B6E0-0C6C4A1B6227Q54335763-43E18668-0820-4EEF-BB9F-5172B0028167Q58694439-2AD3CCC9-FD1F-4FFF-8592-A2B9D9394B55
P2860
TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
TNF-alpha gene expression in c ...... liximab in ulcerative colitis.
@en
TNF-alpha gene expression in c ...... liximab in ulcerative colitis.
@nl
type
label
TNF-alpha gene expression in c ...... liximab in ulcerative colitis.
@en
TNF-alpha gene expression in c ...... liximab in ulcerative colitis.
@nl
prefLabel
TNF-alpha gene expression in c ...... liximab in ulcerative colitis.
@en
TNF-alpha gene expression in c ...... liximab in ulcerative colitis.
@nl
P2093
P1433
P1476
TNF-alpha gene expression in c ...... liximab in ulcerative colitis.
@en
P2093
Guanglin Cui
Ingrid Christiansen
Jon Florholmen
Trine Olsen
P304
P356
10.1016/J.CYTO.2009.02.001
P50
P577
2009-03-14T00:00:00Z